Baijian published the second phase clinical study report of passport of gosuranemab, which did not reach the main end point.

Biovalley / December 13, 2019 - Baijian today announced the main results of the phase 2 passport study of gosuranemab (biib092) on progressive supranuclear paralysis (PSP) The primary endpoint measured by the psprs at week 52 was not statistically significant In addition, the study did not demonstrate efficacy for key clinical secondary endpoints Based on these results, Biogen will stop developing gosuranemab for the treatment of PSP and other primary tauopathies "We are disappointed with the outcome of the passport phase 2 study," said Dr Alfred sandrock, executive vice president and chief medical officer of Baijian research and development "We are firmly committed to promoting therapies that may meet the huge unmet medical needs of patients with neurodegenerative diseases who currently have no treatment options." Gosuranemab (biib092) is a humanized IgG4 monoclonal antibody targeting at N-terminal tau protein (Etau) The basic principle of this treatment is based on the hypothesis that Etau is involved in the transmission of pathological diseases The results showed that the antibody could neutralize the toxicity of Etau in mice model of frontotemporal dementia It has been reported that the secretion form of tau can cause hyperactivity of neurons, which may increase the production of a β, thus aggravating the feedforward cycle Due to the pathological differences of the disease, Biogen will continue the ongoing phase 2 study of gosuranemab of tango, a phase 2 study to evaluate the safety and tolerance of gosuranemab in patients with mild cognitive impairment caused by Alzheimer's disease or Alzheimer's disease From May 2018 to summer 2019, tango is a global phase 2 clinical trial targeting 105 centers of Alzheimer's disease, which recruited 654 participants with mild cognitive impairment caused by ad or mild AD and positive amyloid PET scan The trial will compare three different doses of biib092 or placebo for about 1.5 years per month, followed by three years of extended administration The main result was the number of adverse events Secondary outcomes included changes in the clinical dementia score (cdr-sb) after 1.5 years of treatment, and whether participants produced anti biib092 antibodies The placebo-controlled phase will last until 2021 and the long-term expansion is expected to end in 2024 (Bio Valley / bio Com) original source: Biogen reports top-line results from phase 2 study in progressive superior pallsy